Halt™ 蛋白酶和磷酸酶抑制剂混合物无 EDTA (100X)
Invitrogen17万+抗体限时买二赠一，靶点广，灵活用！
Invitrogen17万+抗体限时买二赠一，靶点广，灵活用！
Halt™ 蛋白酶和磷酸酶抑制剂混合物无 EDTA (100X)
引用和文献 (5)
Thermo Scientific™

Halt™ 蛋白酶和磷酸酶抑制剂混合物无 EDTA (100X)

Thermo Scientific Halt蛋白酶和磷酸酶抑制剂一次性混合物(100X)可通过单一溶液为细胞和组织裂解产物提供蛋白样品保护。Halt蛋白酶及磷酸酶抑制剂一次性混合物(100X)的特点：• 全面保护— 多功能混合物，包含蛋白酶和磷酸酶抑制剂• 多种包装规格— 可方便地在四种规格中进行选择，符合几乎所有与规模实验的要求• 便捷—100x液体配方远比单片抑制剂或其他形式更加易用和高效• 易于储存—与基于DMSO的混合物相比，水相基础的形式便于储存于冷藏室中，而且不需要冷冻•了解更多信息
Have Questions?
更改视图buttonViewtableView
货号数量
784411 mL
7844324 x 100μL
784455 x 1 mL
7844710 mL
货号 78441
价格（CNY)
3,883.00
Each
添加至购物车
数量:
1 mL
请求批量或定制报价
价格（CNY)
3,883.00
Each
添加至购物车
Thermo Scientific Halt蛋白酶和磷酸酶抑制剂一次性混合物(100X)可通过单一溶液为细胞和组织裂解产物提供蛋白样品保护。

Halt蛋白酶及磷酸酶抑制剂一次性混合物(100X)的特点：

• 全面保护— 多功能混合物，包含蛋白酶和磷酸酶抑制剂
• 多种包装规格— 可方便地在四种规格中进行选择，符合几乎所有与规模实验的要求
• 便捷—100x液体配方远比单片抑制剂或其他形式更加易用和高效
• 易于储存—与基于DMSO的混合物相比，水相基础的形式便于储存于冷藏室中，而且不需要冷冻
• 兼容性强— 因不含会导致峰值偏移的 AEBSF 物质，可与质谱分析(MS)兼容
• 经验证— 与Thermo Scientific Pierce细胞裂解缓冲液完全兼容

Halt蛋白酶和磷酸酶抑制剂混合物经过了专门的优化，可以在抽提和纯化过程中保护蛋白质免受降解。该混合物包含主要类别的氨肽酶、半胱氨酸和丝氨酸蛋白酶、丝氨酸/苏氨酸以及酪氨酸蛋白磷酸酶抑制成分。

相关资源：
蛋白酶和磷酸酶抑制剂综述

相关产品：
所有蛋白酶和磷酸酶抑制剂混合物和片剂
仅供科研使用。不可用于诊断程序。
规格
缓冲液裂解缓冲液
描述Halt 蛋白酶和磷酸酶抑制剂混合物，不含EDTA
抑制剂蛋白酶抑制剂、磷酸酶抑制剂
数量1 mL
试剂类型蛋白酶抑制剂、磷酸酶抑制剂
形式液体
产品线Halt
产品类型抑制剂混合物
Unit SizeEach
内容与储存
接收后，储存在 4°C 下。产品在冰袋上运输。切勿冷冻产品。

常见问题解答 (FAQ)

Can I store the 1X solution of the Halt Protease and Phosphatase Inhbitor Cocktail and if so, for how long?

The stability of the 1X solution is undetermined. For best results, prepare solutions just before use. The 100X concentrate is stable for at least one year stored at 4 degrees C.

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

What are the concentrations of the various components of the combined Halt Protease and Phosphatase Inhibitor Cocktail?

Although we reveal the identity of the inhibitors in the combined cocktail, their concentrations are proprietary.

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

Do you offer the components of the Halt Protease and Phosphatase Cocktail individually?

Yes. Halt Protease, Halt Phosphatase and Protease/Phosphatase combined Inhibitor Cocktails are available. In addition, some of the individual inhibitors of the Halt Protease and Phosphatase Inhibitor Cocktail are offered separately.

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

When do I need to add EDTA when using the Halt Protease and Phosphatase Cocktail?

EDTA chelates the metal ions required for metalloprotease activity. Add EDTA if metalloproteases are likely to adversely affect target protein function; however, avoid using EDTA when the downstream application involves metal chelate affinity purification or the target protein requires metals for proper function.

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

How much of the Halt Protease and Phosphatase Cocktail do I use for my sample?

The Halt Protease and Phosphatase Cocktail is supplied at a 100X concentrate and is used at 1X. For example, add 10µL of 100X Halt Cocktail to 1mL of sample. Some samples, however, contain high levels of proteases or phosphatase and might require a more concentrated treatment (i.e., 2-3X).

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

View all Halt™ 蛋白酶和磷酸酶抑制剂混合物无 EDTA (100X) FAQs

引用和文献 (5)

引用和文献
Abstract
Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
Authors:Lowery CD,Blosser W,Dowless M,Knoche S,Stephens J,Li H,Surguladze D,Loizos N,Luffer-Atlas D,Oakley GJ 3rd,Guo Q,Iyer S,Rubin BP,Stancato L
Journal:Clinical cancer research : an official journal of the American Association for Cancer Research
PubMed ID:29191969
Purpose: Platelet-derived growth factor receptor α (PDGFRα) is implicated in several adult and pediatric malignancies, where activated signaling in tumor cells and/or cells within the microenvironment drive tumorigenesis and disease progression. Olaratumab (LY3012207/IMC-3G3) is a human mAb that exclusively binds to PDGFRα and recently received accelerated FDA approval and conditional ... More
Reverse phase protein microarray technology in traumatic brain injury.
Authors:Gyorgy AB,Walker J,Wingo D,Eidelman O,Pollard HB,Molnar A,Agoston DV
Journal:Journal of neuroscience methods
PubMed ID:20674607
Antibody based, high throughput proteomics technology represents an exciting new approach in understanding the pathobiologies of complex disorders such as cancer, stroke and traumatic brain injury. Reverse phase protein microarray (RPPA) can complement the classical methods based on mass spectrometry as a high throughput validation and quantification method. RPPA technology ... More
Distinct roles for Notch1 and Notch3 in human adipose-derived stem/stromal cell adipogenesis.
Authors:Liu MC,Logan H,Newman JJ
Journal:Molecular biology reports
PubMed ID:33021719
The role of the Notch signaling pathway in adipogenesis has long been controversial as the action of individual Notch receptors appears to vary with experimental conditions. In this study, we offer some explanation for the observed contradictions by comparing the role of both Notch1 and Notch3 in regulating the expression ... More
Quantitative PCR analysis of DNA, RNAs, and proteins in the same single cell.
Authors:Ståhlberg A, Thomsen C, Ruff D, Åman P
Journal:Clin Chem
PubMed ID:23014600
The single cell represents the basic unit of all organisms. Most investigations have been performed on large cell populations, but understanding cell dynamics and heterogeneity requires single-cell analysis. Current methods for single-cell analysis generally can detect only one class of analytes. ... More
The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts.
Authors:Id Boufker H, Lagneaux L, Najar M, Piccart M, Ghanem G, Body JJ, Journé F
Journal:BMC Cancer
PubMed ID:20565769
The proto-oncogene Src is an important non-receptor protein tyrosine kinase involved in signaling pathways that control cell adhesion, growth, migration and differentiation. It negatively regulates osteoblast activity, and, as such, its inhibition is a potential means to prevent bone loss. Dasatinib is a new dual Src/Bcr-Abl tyrosine kinase inhibitor initially ... More